Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis
Yukihiro Kaneko1, Katsunori Yanagihara, Masafumi Seki
1The Second Dept. of Internal Medicine, Nagasaki Univ. School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Abstract:
Long-term treatment of macrolide antibiotics is considered an effective treatment for diffuse panbronchiolitis (DPB). Although hypersecretion is a common feature of this disease, and it is known that macrolides inhibit mucin production, the mechanism of the effect on mucin production is unclear. The aim of our study was to determine the production of muc5ac core protein, a major core protein of mucin in airway secretion, and the effect of clarithromycin treatment on such production in a mouse model mimicking DPB. Alcian blue-periodic acid-Schiff-positive cells were detected in the lungs of Pseudomonas aeruginosa-infected mice. Western blots of these mice showed muc5ac glycoprotein at day 1 and increased progressively from day 4 to day 14 after inoculation of bacteria. Clarithromycin (10 mg. kg-1. day-1 for 7 days) significantly reduced the muc5ac expression at both the mRNA and protein levels. To investigate the role of molecules upstream in muc5ac regulation, we examined the role of mitogen-activated protein kinase. Extracellular signal-regulated kinase 1/2 phosphorylation increased in the infected lung and decreased after treatment. Our results suggest that overproduction of muc5ac plays an important role in the pathogenesis of DPB and that clinical improvement following macrolide therapy seems to involve, at least in part, its inhibition of mucin overproduction, through modulation of intracellular signal transduction.
Insights
Macrolide antibiotics like clarithromycin reduce MUC5AC protein in diffuse panbronchiolitis (DPB) models. This study shows clarithromycin inhibits mucin overproduction, potentially explaining its therapeutic effects in DPB.
Area of Science:
- Pulmonary Medicine
- Microbiology
- Cellular Biology
Background:
- Diffuse panbronchiolitis (DPB) is often treated with macrolide antibiotics.
- Hypersecretion is a key feature of DPB, and macrolides are known to inhibit mucin production, but the mechanism is unclear.
Purpose of the Study:
- To investigate MUC5AC core protein production in a mouse model of DPB.
- To determine the effect of clarithromycin on MUC5AC production and related signaling pathways.
Main Methods:
- A mouse model of DPB was established using Pseudomonas aeruginosa infection.
- Alcian blue-periodic acid-Schiff staining, Western blotting, and analysis of mitogen-activated protein kinase (MAPK) signaling were performed.
- Mice were treated with clarithromycin.
Main Results:
- Pseudomonas aeruginosa infection led to increased MUC5AC glycoprotein expression at both mRNA and protein levels.
- Clarithromycin treatment significantly reduced MUC5AC expression.
- Extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation, a MAPK pathway component, increased with infection and decreased with clarithromycin treatment.
Conclusions:
- MUC5AC overproduction is implicated in DPB pathogenesis.
- Macrolide therapy, such as clarithromycin, may exert clinical benefits by inhibiting mucin overproduction.
- Modulation of intracellular signaling pathways, including MAPK, is involved in the mechanism of macrolide action in DPB.
Related Concept Videos
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...


